product name Biapenem
Description: Biapenem (also called L-627, LJC10627) is a carbapenem antibiotic with activity against both Gram-positive and Gram-negative bacterial strains. Biapenem has activity comparable to those of Imipenem and Meropenem against all groups of anaerobes with MICs for 90% of the strains tested of 0.06 to 2 mg/mL. Biapenem is more active than ampicillin-sulbactam, ticarcillin-clavulanate, piperacillin, cefoxitin, cefotaxime, and ceftriaxone. Biapenem is also active against all of the B. capillosus, Prevotella, Clostridium, and Eubacterium strains and anaerobic cocci tested. Biapenem shows broad antibacterial activity against both Gram-positive and Gram-negative clinical isolates.
References: Antimicrob Agents Chemother. 1994 Apr;38(4):889-93; Jpn J Antibiot. 2003 Apr;56(2):138-41; J Infect Chemother. 2012 Aug;18(4):472-8.
350.39
Formula
C15H18N4O4S
CAS No.
120410-24-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: <1 mg/mL
Water: 16 mg/mL (45.7 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
L-627, LJC10627
other peoduct :
| In Vitro |
In vitro activity: Biapenem has activity comparable to those of Imipenem and Meropenem against all groups of anaerobes with MICs for 90% of the strains tested of 0.06 to 2 mg/mL. Biapenem is more active than ampicillin-sulbactam, ticarcillin-clavulanate, piperacillin, cefoxitin, cefotaxime, and ceftriaxone. Biapenem is also active against all of the B. capillosus, Prevotella, Clostridium, and Eubacterium strains and anaerobic cocci tested. Biapenem shows broad antibacterial activity against both Gram-positive and Gram-negative clinical isolates. Biapenem is found to be approximately as active as imipenem, inhibiting 90% of isolates of most species at concentrations within one dilution of the MIC of imipenem for 90% of the isolates. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Biapenem results in significantly fewer viable bacteria than in the lungs of control mice. Biapenem prevents the progression of lung inflammation, including alveolar neutrophil infiltration and hemorrhage. Biapenem significantly prolongs survival and reduces the number of viable bacteria in a murine model of VAP caused by P. aeruginosa. |
| Animal model | |
| Formulation & Dosage | |
| References | Antimicrob Agents Chemother. 1994 Apr;38(4):889-93; Jpn J Antibiot. 2003 Apr;56(2):138-41; J Infect Chemother. 2012 Aug;18(4):472-8. |
